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response elicited in prime-boost regimen 
by viral vector encoded homologous SIV Gag/
Env in outbred CD1 mice
Anne‑Marie Carola Andersson* and Peter Johannes Holst*
Abstract 
Background: A major obstacle for the development of HIV vaccines is the virus’ worldwide sequence diversity. Nev‑
ertheless, the presence of T cell epitopes within conserved regions of the virus’ structural Gag protein and conserved 
structures in the envelope (env) sequence raises the possibility that cross‑reactive responses may be induced by 
vaccination. In this study, the aim was to investigate the importance of antigenic match on immunodominance and 
breadth of obtainable T cell responses.
Methods: Outbred CD1 mice were immunized with either heterologous (SIVmac239 and HIV‑1 clade B consensus) 
or homologous (SIVmac239) gag sequences using adenovirus (Ad5) and MVA vectors. Env (SIVmac239) was co‑
encoded in the vectors to study the induction of antibodies, which is a primary target of current HIV vaccine designs. 
All three vaccines were designed as virus‑encoded virus‑like particle vaccines. Antibody responses were analysed by 
ELISA, avidity ELISA, and neutralization assay. T cell responses were determined by intracellular cytokine staining of 
splenocytes.
Results: The homologous Env/Gag prime‑boost regimen induced higher Env binding antibodies, and induced 
stronger and broader Gag specific CD8+ T cell responses than the homologous Env/heterologous Gag prime‑boost 
regimen. Homologous Env/heterologous Gag immunization resulted in selective boosting of Env specific CD8+ T cell 
responses and consequently a paradoxical decreased recognition of variant sequences including conserved elements 
of p24 Gag.
Conclusions: These results contrast with related studies using Env or Gag as the sole antigen and suggest that 
prime‑boost immunizations based on homologous SIVmac239 Gag inserts is an efficient component of genetic VLP 
vaccines—both for induction of potent antibody responses and cross‑reactive CD8+ T cell responses.
Keywords: Adenoviral vectors, Human immunodeficiency virus, Vaccine, Virus‑like particles
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The ideal human immunodeficiency virus (HIV) vac-
cine should likely activate both the humoral and the cel-
lular arm of the immune system; enabling antibodies to 
neutralize incoming virus particles while CD8+ T cells 
would kill already infected cells and limit the spread of 
the virus.
The substantial role of CD8+ T cells in the control of 
HIV type 1 (HIV-1) infection is supported by the corre-
late of protection with specific HLA class I allotypes [1–
4], a temporary decline in peak viremia coinciding with 
appearance of CD8+ T cell responses during acute infec-
tion [5, 6], and occurrence of escape mutants in response 
to specific CD8+ T cells [7, 8]. In humans, protective 
CD8+ T cell responses have been found to correlate with 
Open Access
Journal of 
Translational Medicine
*Correspondence:  annema@sund.ku.dk; pholst@sund.ku.dk 
Department of Immunology and Microbiology, Center for Medical 
Parasitology, University of Copenhagen, Copenhagen, Denmark
Page 2 of 10Andersson and Holst  J Transl Med  (2016) 14:343 
the targeting of Gag [9, 10] and possibly of Nef [11], while 
inversely correlating with responses against envelope 
(Env) [10]. These correlations have been substantiated 
by additional population studies that have generated in-
depth data by carefully screening responses to the HIV-1 
proteome and investigating protective responses towards 
individual epitopes [12–17]. Together, these studies indi-
cate that it is theoretically possible to successfully target 
HIV-1 by inducing T cells targeting specifically effective 
epitopes. However, such protective T cell specificities 
have only been raised infrequently after immunization 
with full length HIV-1 antigens [18] and previous vacci-
nation attempts that aimed to induce CD8+ T cells have 
failed to control HIV-1 replication overall [19]. Despite 
their overall clinical failure, these studies did provide evi-
dence of improved virus control after polyspecific target-
ing of defined regions of Gag, Vif, Nef, and Pol [18, 20]. A 
shift to more focused constructs aimed to direct CD8+ 
T cells specifically to carefully selected regions has there-
fore been a logical step forward. Conserved regions vac-
cines [14, 21] and conserved elements (CE) vaccines [22] 
each represents approaches aiming to overcome the chal-
lenge of HIV-1 diversity and raise responses to rarely tar-
geted, yet protective specificities [23].
While T cell based vaccines have yet to show efficacy 
in clinical trials, the RV144 trial demonstrated the pos-
sibility of reducing infection risk by raising Env specific 
antibodies with a virus-like particle (VLP) encoded virus 
vectored prime and a protein boost vaccine [24]. A recent 
interest in the coordinated responses against Gag and 
Env has emerged. Studies by Schell et al. suggested that 
Gag benefits a response based on protective antibod-
ies in a vaccine secreting VLPs [25, 26]. Additionally, the 
immune response against Gag has been shown to sup-
port antibody responses against Env displayed on VLPs 
by providing an additional source of intrastructural T cell 
help [27, 28].
Due to the additive and potentially synergistic value 
of using Gag and Env for effective antibody and T cell 
mediated protection, we sought to study the induction 
of potentially protective Gag and Env responses in VLP 
based virus vectored immunization regimens. To inves-
tigate the possibility of inducing T cell responses against 
conserved or cross-reactive epitopes in the Gag poly-
protein, while preserving antibody responses towards 
Env trimers in such a virus vectored VLP vaccine con-
struct, we used a prime-boost regimen with heterolo-
gous Gag together with homologous Env and compared 
it to a homologous Gag/Env regimen. We did this by 
utilizing a combination of adenoviral vectors co-encod-
ing SIVmac239 env and either HIV-1 or SIVmac239 
gag sequences as primers for modified vaccinia Ankara 
(MVA) vectors encoding SIVmac239 env and SIVmac239 
gag. We included a non HIV sequence as previous studies 
have found no benefit of prime-boost regimens using Gag 
from different HIV clades while improved breadth was 
found using different HIV Env clade sequences [29, 30]. 
Using SIV and HIV Env provides a diversity resembling 
the successful heterologous Env sequences and results in 
a vaccine design immediately testable in a non-human 
primate model. Here we show that outbred CD1 mice 
immunized with homologous Gag/Env had an increased 
breadth and functionality of T cell responses against het-
erologous gag sequences as well as a surprising increased 
magnitude of Env specific antibody responses. Mice 
immunized with homologous Gag selectively expanded 
Gag specific T cells following the booster immunization 
whereas mice immunized with heterologous Gag selec-
tively expanded Env specific T cells following the boost. 
These data highlights the importance in the selection of 
gag sequences in VLP encoding virus vectored immuni-
zation regimens.
Methods
Mice
Female CD1 mice at the age of 6–8 weeks were obtained 
from Scanbur (Denmark). The mice were allowed to 
acclimatize for one week prior to the initiation of an 
experiment. All experiments were performed accord-
ing to national guidelines and experimental protocols 
approved by the national animal experiments inspector-
ate (Dyreforsøgstilsynet).
Adenoviral vaccine production
HIV-1 clade B consensus (HIV-1 CON B) or SIVmac239 
gag was encoded after a CMV promoter, followed by a 
self-cleavable P2A peptide and then by SIVmac239 env 
and SV40 polyA. The expression cassette was cloned 
into a human adenovirus type 5 backbone and produced, 
purified and titered as described [31]. A modified vac-
cinia Ankara (MVA) vaccine encoding SIVmac239 gag, 
pol, env (truncated at aa 733) (MVAgpe) [32] was kindly 
provided by Dr. Patricia Earl (Laboratory of Viral Dis-
eases, NIH). The vaccine was amplified and titered in pri-
mary chicken embryoblasts according to the protocols in 
Kramer et al. [33].
Purification of vaccine encoded VLPs for further 
characterization
Vero cells were infected with 50 plaque forming units 
(PFU)/cell of either Ad5 vaccine, supernatants harvested 
48 h post infection, and VLPs concentrated as previously 
described [31]. Pellets were resuspended in PBS at 280 X 
of the original concentration.
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Western blot analysis
VLPs purified from Ad5 infected vero cells were prepared 
as previously described [31] and characterized by western 
blot. Env was detected with the SIVmac251 gp120 spe-
cific monoclonal antibody (mAb) KK46 [34] [NIH AIDS 
Research and Reference Reagent Program (NARRRP)] 
followed by HRP coupled goat anti-mouse immunoglob-
ulin antibody (Dako). The same blot was analysed for the 
presence of Gag using HIV-1 anti-p24 mAb 183-H12-5C 
[35] (NARRRP), and goat anti-mouse immunoglobulin 
antibody (Dako). SIVmac239 gp130 [36] and SIVmac251 
BK28 pr55 Gag were loaded as positive controls (NAR-
RRP). The blots were developed using ChemiLucent 
Detection System kit (Pierce). Analysis was performed 
using Image Studio Lite software (LI-COR Biosciences).
Cell surface expression analysis
Env expression was analysed on the surface of vero cells 
2  days after infection with 50  PFU/cell of either Ad5 
vaccine. Cells were stained with the ITS52, ITS03, and 
ITS40 mAbs [37] (kindly provided by Dr. Mario Roederer, 
VRC, NIAID, NIH). Binding of the mAbs was detected 
using anti-human IgG Fc-APC antibody (BioLegend), 
and the cells were acquired using an LSRII instrument 
(BD Biosciences) and analysed with FlowJo software 
(Tree Star, Ashland, OR).
Immunizations
Groups of mice (5 or 10 per group) were immunized 
intramuscularly (i.m.) with 2 ×  108  IFU with either Ad5 
vaccine. Where indicated, mice were boosted i.m. 59 days 
after priming with 1 × 107 IFU of MVAgpe. Vaccines were 
applied in a total volume of 50 μl PBS in the quadriceps 
muscle, changing legs at each immunization time-point.
Antibody response measurements
Antibody responses against SIVmac239 Env were deter-
mined in a concanavalin A (ConA) (Sigma-Aldrich) 
enzyme linked immunosorbent assay (ELISA) as adapted 
from [38]. SIVmac239 Env was produced in 293FT cells 
by co-transfection of a shuttle plasmid encoding SIV-
mac239 Env and the plasmid pSG3Δenv [39] (NARRRP). 
ELISA was performed as described elsewhere [31]. Avid-
ity measurements were performed simultaneously with 
antibody response measurements as adapted from [38], 
using 0.1  M sodium citrate buffer (pH 3.0). The avidity 
index was calculated by dividing the titer obtained with 
sodium citrate treatment by the titer obtained without 
sodium citrate treatment, and multiplied by 100.
SIV Env pseudovirus production and titration
The Env constructs for SIVmac239 and SIVsmE660.11 
pseudovirus production were obtained from Dennis 
Burton (The Scripps Research Institute) and David C. 
Montefiori (Duke University), respectively. Production 
and determining TCID has been described elsewhere 
[40].
Neutralization assay
Neutralization of pseudoviruses was measured in TZM-
bl cells following the protocols in Montefiori [40]. To 
account for unspecific binding to either pseudovirus, 
pooled pre-immunization serum samples were analysed 
at a dilution of 1:20. SIVmac251 antiserum [41] (NAR-
RRP) was included as a control. Neutralization against 
SIVmac239 was assayed in pools of 4–5 mice per group. 
The SIVmac239 pseudovirus did not achieve the RLU of 
10 times the background (5.2 times the RLU of the back-
ground), but was included in the analysis since it was 
clear that there was no neutralization in neither sample 
that was tested.
Intracellular cytokine staining
Intracellular staining was performed on splenocytes 
using a standard protocol [42] using 0.67  μg/ml HIV-1 
CON B Gag pool, SIVmac239 Gag pool, SIVagm vervet 
Gag pool, SIVmac239 Env pool, CE pools for the three 
different Gags respectively) (all from NARRRP) at 37 °C 
and 5% CO2. Based on definitions by [22], CE pools were 
prepared from peptides spanning the CE from whole 
Gag peptide sets. The following antibodies were used 
for detection (Biolegend): CD8_PerCP.Cy5.5, CD4_
FITC, B220_Pacific Blue, CD44_APC.Cy7, IFN-γ_APC, 
TNF-α_Pe.Cy7. The cells were acquired using an LSRII 
instrument (BD Biosciences) and analysed with FlowJo 
software (Tree Star, Ashland, OR). One mouse was 
excluded from the T cell analysis due to the collection of 
too few events.
Statistical analysis
Nonparametric Mann–Whitney tests were performed 
for analysis of differences between the groups. Spear-
man rank testing followed by Holms correction for mul-
tiple comparisons was used to assess correlations. The 
ID50 values in the neutralization assay were calculated 
in Graph Pad Prism using an asymmetric curve fitting (5 
parameters). Statistical analyses were performed using 
either the R statistical software or Graph Pad Prism. p 
values <0.05 were considered significant.
Results
Vaccine design and characterization
To enable shift of the gag sequence in otherwise identi-
cal viral vectored prime-boost regimens, we encoded 
SIVmac239 env with either a SIVmac239 gag sequence 
(AdSgSe), or HIV-1 CON B gag sequence (AdHgSe) in 
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individual Ad5 encoded VLP expression cassettes for 
use as priming vaccines (Fig.  1a). The adenovirus vec-
tors were used as priming immunogens for MVA vectors 
encoding SIVmac239 gag, pol and env (MVAgpe) likewise 
designed to secrete VLPs [32]. T cell immune responses 
were analysed to vaccine incorporated gag sequences and 
a more distantly related gag sequence (SIVagm vervet). 
We chose the SIVmac239 gag sequence and the HIV-1 
CON B gag sequence to study heterologous Gag immu-
nization in virus-vectored VLPs in a vaccine design suit-
able for nonhuman primate testing. SIVagm vervet was 
chosen to measure cross-reactive responses as it had 
the same sequence similarity to either HIV-1 CON B 
gag or SIVmac239 gag, and similar similarity to these as 
the similarity between HIV-1 CON B and SIVmac239 
gag (illustrated in Fig.  1b). The two Ad5 vaccines were 
characterized for VLP secretion of the respective vac-
cine antigens in the supernatant of vaccine infected vero 
cells. VLPs were collected and Gag and Env content was 
assessed by western blotting (Fig.  1c). We detected the 
expression of Gag with the HIV-1 p24 mAb 183-H12-5C, 
previously shown to cross-react with SIVmac239 Gag 
[43]. Bands for both pr55 and pr55 cleavage products 
were observed for both constructs. For Env, both gp120 
and gp160 bands were visible by probing with the gp120 
specific mAb KK46. The MVAgpe vaccine had been char-
acterized previously and this analysis was not repeated 
here except for verification of Env expression by immu-
nocytochemistry (not shown and [32, 44]).
Surface staining of vero cells confirmed the expression 
of Env from both Ad5 vaccines. An increase in cell surface 
binding for the three antibodies utilized for analysis (ITS52, 
ITS03, ITS40) was observed for the vaccine AdHgSe 
compared to the AdSgSe vaccine (Fig.  1d). Both vaccines 
exhibited lower binding to the V3 specific mAb ITS52 as 
compared to the V2 specific mAbs ITS03 and ITS40, but 
except for the quantitative difference in cell surface binding, 
the two vaccines stained similarly with each antibody indi-
cating similar presentation of the conformational epitopes 
recognized by these antibodies [37], (Fig. 1e).
Heterologous and homologous Gag prime‑boost regimen
The use of the two adenovirus vectors, AdHgSe and 
AdSgSe, and the MVAgpe vector allowed us to prime 
with either HIV-1 CON B Gag or SIVmac239 Gag fol-
lowed by boost with SIVmac239 Gag, while keeping the 
SIVmac239 Env constant in the prime-boost regimen. 
Blood samples for antibody analysis were taken a week 
prior to boosting immunization and also 10  days post 
boost, at the same time as the spleens were harvested 
for T cell analysis (Fig. 2a), as this was anticipated as the 
time of maximal T cell responses [45] and peak antibody 
responses following an MVA booster immunization [46].
a
b c
d
e
Fig. 1 Vaccine design and vaccine characterization. a Schematic rep‑
resentation of Ad5 vectors encoding either SIVmac239 gag or HIV‑1 
CON B gag, P2A preceded by a glycine‑serine‑glycine linker (not 
noted in the figure), and SIVmac239 env. The inserted antigens were 
flanked by huCMV and a SV40 polyadenylation signal. b Phylogenetic 
tree of Gag used in the Ad5 vaccines and for analysis. The distance 
values show the number of substitutions as a proportion of the 
length of the alignment (here excluding gaps). Upper panel is analysis 
of Gag and lower panel is analysis of p24 CE. Mu murine leukemia 
virus, used as an outlier; H HIV‑1 CON B Gag; M SIVmac239 Gag; V 
SIVagm vervet Gag. c Gp160 and gp120 were detected in ultra cen‑
trifuge purified VLPs from the supernatants of Ad5 infected vero cells 
by SDS‑PAGE (reduced) followed by western blot. SIVmac251 specific 
mAb KK46 was used for detection of gp120. Pr55 Gag and pr55 Gag 
cleavage products were detected using 183‑5C‑H12 HIV‑1 p24 spe‑
cific mAb. SIVmac239 gp130 and SIVmac251 BK28 pr55 Gag served 
as positive controls for gp120 and pr55 respectively. c is control lane. 
d Surface staining of vero cells infected with Ad5 vaccines (50 PFU/
cell, 25 µg/ml mAb) or uninfected with indicated mAbs. e Ratio of 
AdHgSe to AdSgSe mAb binding calculated as mean fluorescence 
intensity × positively gated fraction. Calculations were performed on 
cells infected with 50 PFU/cell of either vaccine as in d, using 25 or 
2.5 µg/ml mAb concentration. Shown are calculated ratios from two 
independent assays with the mean marked by horizontal lines
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Humoral responses
Env responses against VLP derived SIVmac239 Env 
were analysed 52 days post 1st immunization (Ad5) and 
10  days post (d. 69) the second immunization (MVA). 
Differences in immune responses were observed between 
the two Ad5 priming regimens both after the first immu-
nization and after the MVAgpe boost (Fig.  2b). Mice 
primed with AdSgSe had significantly higher end point 
titers against pseudovirus derived Env at both time-
points (p  <  0.05 and <0.01, respectively). Boosting with 
MVAgpe increased the mean responses eightfold for 
the AdSgSe primed group, and fourfold for the AdHgSe 
primed group. Mice  that had only been primed with 
either Ad5 vaccine showed approximately a twofold 
decrease in Env responses after 69  days as compared 
to 52  days post immunization. Still, at this time-point, 
69 days post immunization; titers remained significantly 
higher for the group immunized with AdSgSe as com-
pared to AdHgSe (p < 0.05).
The immunoglobulin avidity was also determined 
in the two groups of mice that had received boost-
ing immunizations with no observed differences in the 
immunoglobulin avidity index between the immuniza-
tion regimens either before or after the boost (data only 
shown after boost) (Fig. 2c).
Neutralizing responses were determined against 
SIVsmE660.11, categorized as a neutralization sensi-
tive tier 1 [47]. The ID50 titers were analysed for the two 
groups of mice that had been boosted with MVAgpe. 
Mice primed with AdSgSe, all had detectable ID50 titers, 
while the ID50 titers of 3 mice in the AdHgSe primed 
group were below the chosen start dilution of 1:500 for 
detection (Fig. 2d).The geometric mean titers were simi-
lar; hence, no significant differences were detected. Neu-
tralization was also analysed in pools of 4–5 mice against 
the homologous SIVmac239, classified as a neutralization 
resistant tier 3, with no neutralizing responses detected 
(data not shown).
T cell responses to homologous and distantly related Gag 
sequences
The frequency and epitope specificity of T cell responses 
were analysed by intracellular cytokine staining on 
splenocytes 10  days after the MVA boost (69  days post 
prime). Responses were analysed against the vaccine anti-
gens, and against SIVagm vervet Gag (Fig. 1b), to reveal 
the breadth and/or the cross-specificity of the responses. 
The homologous boost was found to increase mean 
responses towards all 3 complete Gag peptide pools, 
whereas the heterologous boost induced HIV-1 CON B 
a
b
c d
Fig. 2 The magnitude of SIVmac239 Env responses is dependent 
on the co‑encoded gag sequence. CD1 mice were primed with 
Ad5 vaccines co‑encoding SIVmac239 env with either SIVmac239 
gag (AdSgSe) or HIV‑1 CON B gag (AdHgSe) as illustrated in the 
experimental outline (a). Asterisk indicates time of serum harvest. (#) 
indicates harvest of spleens. 10 respectively 9 mice from each group 
were then boosted with MVA encoding SIVmac239 gag, pol, and env 
(MVAgpe) truncated at amino acid 733. Immunogenicity was inves‑
tigated 52 and 69 days post priming immunization and also 10 days 
post boosting with MVA (d.69). b Co‑encoding SIVmac239 gag 
compared to HIV‑1 CON B gag with SIVmac239 env led to significantly 
increased end point titers against SIVmac239 Env, both after priming 
immunization, and also after the MVA boost. c The Avidity Index 
was determined in the sodium citrate displacement assay against 
SIVmac239 Env. d Neutralization titers against SIVsmE660.11 were 
determined at serum dilution starting at 1:500 (indicated with dotted 
line). b–d depicts individual mice with horizontal lines indicating 
mean with SEM (b) or geometric mean (c, d)
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biased responses that were not increased after the boost 
(Fig.  3a). Also, quite prominently, the homologous Gag 
immunization induced significantly higher CD8 + IFN-γ 
responses against SIVagm vervet Gag. Examination of 
T cell responses to CE within p24 of Gag revealed that 
heterologous Gag immunization was not beneficial for 
the induction of conserved p24 responses either (Fig. 3b). 
Instead, homologous Gag immunization induced signifi-
cantly higher CD8  +  IFN-γ responses against SIVagm 
vervet CE, with similar responses towards the CE in 
HIV-1 CON B Gag. A generally higher magnitude of 
responses against SIVmac239 Gag CE was also observed 
in the homologous vaccination group compared to the 
heterologous vaccination group, and prominent respond-
ers was restricted to this group (5/10), but this difference 
was not significant using non-parametric statistics.
Analysis of the frequency of T cell responses against 
SIVmac239 Env showed that heterologous Gag immuni-
zation led to significantly higher CD8 + IFN-γ responses 
against SIVmac239 Env (p  <  0.05) (Fig.  4). The MVA 
immunization increased the responses by 30-fold in 
this group as compared to homologous Gag where the 
responses were insignificantly expanded, and only by 
approximately fourfold. The CD4+ T cell responses 
against Env in these two groups were very similar (Fig. 4).
CD4 + T cell responses were also determined against 
whole protein of Gag variants and CE variants revealing 
generally low numbers of CD4 + IFN-γ responses against 
variants of Gag and CE (Fig. 5a, b).
Correlations between different T cell specificities 
and between T cells and antibody responses
Spearman rank correlations were determined within the 
groups for the measured Gag specific CD8+ T cell spe-
cificities and the multiple comparisons were corrected 
using Holm’s correction. Possible synergistic T and B cell 
responses were also addressed.
In homologous Gag immunization, CD8  +  IFN-γ 
responses against SIVagm vervet CE correlated with 
HIV-1 CON B CE CD8  +  IFN-γ responses (p  <  0.05) 
(Fig. 6a). Similarly, CD8 + IFN-γ responses against SIV-
mac239 CD8  +  IFN-γ CE responses correlated with 
HIV-1 CON B CE CD8 + IFN-γ responses (p < 0.05), but 
not significantly with SIVagm vervet CE responses fol-
lowing correction for multiple comparisons.
In heterologous immunization, CD8  +  IFN-γ 
responses against SIVagm vervet Gag correlated with its 
CE response (Fig. 6b).
Notably, the heterologous vaccination regimen showed 
a negative correlation between CD8  +  IFN-γ T cell 
a
b
Fig. 3 Heterologous Gag immunization does not induce more cross 
reactive T cell responses. At day 69 mice were sacrificed and spleens 
were harvested for analysis of vaccine induced T cell responses 
against HIV‑1 CON B Gag, SIVmac239 Gag, and SIVagm vervet Gag.  
a Number of IFN‑γ positive CD8+ T cells measured at day 69 against 
full length Gag. b Number of IFN‑γ positive CD8+ T cells measured 
at day 69 against CE of the three Gag variants. Shown are calculated 
total numbers of responding CD8+ T cells per spleen of individual 
mice. Horizontal lines depict the mean of the groups
Fig. 4 Heterologous Gag immunization induces high numbers of 
Env specific CD8+ T cells. Mice were analysed for respective CD4+ 
and CD8+ T cell responses at day 69 upon sacrifice and harvest of 
spleens for analysis. Frequency of IFN‑γ positive CD8+ and CD4+ T 
cells against SIVmac239 Env. Shown are calculated total numbers of 
responding CD8+ T cell per spleen of individual mice. Horizontal lines 
depict the mean of the groups
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responses against Env to neutralizing antibody responses 
against SIVsmE.660.11 (p < 0.05), but a positive correla-
tion trend with the avidity of anti-Env immunoglobu-
lins (p  =  0.05454) (Fig.  6d). No correlations between 
CD8  +  IFN-γ responses against Env and humoral 
responses were observed for the homologous vaccination 
regimen (Fig. 6c).
Discussion
The effect of the VLP scaffold Gag on the strength of 
virus encoded VLP vaccine induced T cell and antibody 
response has not been investigated previously, nor has 
the effect of using different gag sequences in heterolo-
gous prime-boost VLP encoding vaccines. In our analy-
sis of antibody responses we found significantly higher 
Env immunoglobulin titers induced by the homologous 
Gag prime-boost regimen. In contrast, the two different 
immunization regimens induced similar levels of neu-
tralizing antibodies against the neutralization sensitive 
tier 1 SIVsmE660.11, and also similar avidity of anti-Env 
antibodies. More interesting, in addition to higher Env 
binding titers, the analysis of T cell responses revealed 
a superiority of the homologous Gag regimen; also at 
inducing broader CD8+ T cell responses against Gag. 
a
b
Fig. 5 Frequency of CD4+ T cells against Gag and CE. a Splenocytes 
were harvested at day 69 and CD4+ T cells were analysed for their 
responses against Gag variants (a) and CE variants (b). Shown are 
calculated total numbers of responding CD4+ T cell per spleen of 
individual mice. Horizontal lines depict the mean of the groups
Gag CE Gag CE Gag CE
1 1 1 0.0076 1
(-0.304) (-0.164) (-0.467) (0.891) (-0.139)
0.3932 0.051 0.0141 1 0.0333
(-0.304) (0.809) (0.869) (-0.249) (0.833)
0.6515 0.0046 0.061 1 0.0001
(-0.164) (0.809) (0.794) (-0.127) (0.964)
0.1739 0.0011 0.0061 1 0.1422
(-0.467) (0.869) (0.794) (-0.43) (0.733)
0.0005 0.4874 0.7261 0.2145 1
(0.891) (-0.249) (-0.127) (-0.430) (-0.176)
0.7009 0.0028 0.00001 0.0158 0.6272
(-0.139) (0.833) (0.964) (0.733) (-0.176)
CE
SIVmac239
HIV CON B SIVagm vervet SIVmac239
Gag
CE
HIV CON B
Gag
CE
SIVagm 
vervet
Gag
Gag CE Gag CE Gag CE
1 1 1 1 1
(0.619) (0.359) (0.464) (0.464) (0.571)
0.1017 1 0.6802 0.468 1
(0.619) (0.587) (0.683) (0.732) (0.452)
0.3821 0.1262 0.0002 1 0.2227
(0.359) (0.587) (0.982) (0.491) (0.802)
0.2473 0.0618 0.00001 1 0.2227
(0.464) (0.683) (0.982) (0.500) (0.805)
0.2473 0.039 0.2168 0.207 1
(0.464) (0.732) (0.491) (0.500) (0.220)
0.139 0.2604 0.0165 0.0159 0.6013
(0.571) (0.452) (0.802) (0.805) (0.220)
HIV CON B SIVagm vervet
SIVmac239
Gag
CE
SIVmac239
HIV CON B
Gag
CE
SIVagm 
vervet
Gag
CE
CD8+ 
Env Avidity Titer Neut.
0.05454 1 0.03736
(0.815) (0.069) (-0.850)
0.01364 1 0.02984
(0.815) (-0.093) (-0.870)
0.87153 0.82714 1
(0.069) (-0.093) (0.159)
0.00747 0.00497 0.7068
(-0.850) (-0.870) (0.159)
Titer
Neut.
CD8+ 
Env
Avidity
CD8+ 
Env Avidity Titer Neut.
1 1 1
(-0.062) (0.271) (-0.139)
0.86504 1 0.20663
(-0.062) (0.058) (-0.669)
0.44948 0.8738 1
(0.271) (0.058) (0.189)
0.70093 0.03444 0.60138
(-0.139) (-0.669) (0.189)
CD8+ 
Env
Avidity
Titer
Neut.
a
b
c
d
Fig. 6 Correlation data of CD8 + IFN‑γ responses and humoral 
responses. a Correlations between CD8 + IFN‑γ responses towards 
the different Gag and CE in the homologously boosted mice. b Cor‑
relations between CD8 + IFN‑γ responses towards the different Gag 
and CE in the heterologously boosted mice. c Correlations between 
CD8 + IFN‑γ responses and humoral responses towards Env in the 
homologously boosted mice. d Correlations between CD8 + IFN‑γ 
responses and humoral responses towards Env in the heterolo‑
gously boosted mice. Exact p values are written within the cells with 
correlation coefficients shown in parenthesis. The lower left depicts 
uncorrected p values while the upper right depicts p values obtained 
after Holms correction for multiple comparisons. Dark gray shadow 
refers to p < 0.01, light grey shadow refers to p < 0.05. CD8+ Env is 
CD8 + IFN‑γ responses against Env. Titer is end point titers at day 69. 
Neut is neutralizing responses at day 69
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Interestingly, and perhaps retrospectively explainable, it 
appeared that while Gag showed expected CD8+ T cell 
immunodominance over Env, homologous Env showed 
immunodominance over heterologous Gag in a prime-
boost regimen.
Our investigation of conserved T cell responses and the 
selection of CE peptide pools for analysis has its founda-
tion in studies by Kulkarni et  al. [22, 23, 48], who have 
designed an antigen combining only conserved parts of 
p24 of Gag that normally correlates with increased virus 
control, and are found to include epitopes that cannot 
be mutated without virus fitness loss. Our homologous 
full-length Gag prime-boost regimen increased both the 
magnitude and breadth to full length Gag variants and 
CE, with the induced CE responses generally correlat-
ing with the overall responses to different virus variants. 
Bimodal responses were observed in particular for CE for 
both CD4+ and CD8+ T cells, reflecting the harbour-
ing of different MHC alleles in CD1 mice. Heterologous 
Gag immunization did induce some CE responses, albeit 
not the cross-reactive responses that we had expected, 
reflecting the preferential Env specific T cell expansion 
in this group that appeared to come at the expense of 
negligible boosting of Gag specific responses. Compared 
to our results, Kaufman et  al. reported an intermediate 
effect where heterologous full length insert in a prime-
boost regimen neither increased, nor decreased the 
responses against conserved epitopes of Gag, but this 
included the weakly immunogenic Ad35 vector in the 
prime-boost regimen and no env was encoded [29]. The 
inclusion of Env in our prime-boost vaccinations likely 
makes a profound difference as the MVA immunization 
only boosted homologous CD8+ T cell responses in our 
study, and it would appear that homologous responses 
must have blocked expansion of potentially cross-reactive 
T cells recognizing the heterologous boosted antigens. A 
mechanism for how such preferential boosting of homol-
ogous antigens can increase breadth, as compared to a 
heterologous boost where conserved sequence specific 
T cells are preferentially re-stimulated, may have been 
provided by Kelly et  al. [49] who found dominant and 
highly immunogenic epitopes to be effective at selecting 
for cross-reactive T cell responders, and Varela-Rohena 
et  al. [50] who observed increased cross-reactivity of T 
cell receptors mutated for increasing affinity.
With regards to antibodies, both of the prime-boost 
immunization regimens analysed here had increasing 
antibody titers after being boosted. The priming vac-
cine encoding HIV-1 CON B gag was inferior in priming 
Env responses, having significantly lower antibody titers 
7  weeks after priming and also 10  weeks post priming. 
These results implicate the benefit of SIVmac239 Gag 
as a VLP scaffold for induction of a binding antibody, 
although we could not observe any clear differences in 
the VLPs or transduced cells likely to explain this benefit. 
We also observed a fourfold difference in the geometric 
mean titers between the boosted groups; however, both 
the avidity of the anti-Env responses and neutralizing 
responses against SIVsmE660.11 were roughly similar.
An intriguing aspect of our findings is if the immuno-
dominance interplay between Gag and Env and poten-
tially other antigens in prime-boost regimens is also 
playing a role after infection in vaccinated hosts. We 
have observed vaccine induced changes in post-exposure 
epitope targeting in inbred animals challenged with lym-
phocytic choriomeningitis virus [51], but this study is 
the first to report Env immunodominance over Gag at 
the whole antigen level in outbred animals. In SIV mod-
els, immunodominant responses towards easily mutated 
epitopes have been found to delay responses towards 
other epitopes that are harder for the virus to mutate, 
thus reducing the effect of vaccination [52]. In summary, 
our study demonstrates that interantigenic immuno-
dominance is a critical parameter in prime-boost regi-
mens. Future optimization of this and related regimens 
should include both heterologous Env and homologous 
SIV Gag antigens before nonhuman primate efficacy 
trials.
Conclusions
Our study demonstrates the profound impact the choice 
of Gag can have, when used as a VLP scaffold in prime-
boost regimens, on both antibody responses and T cell 
responses. The broad and increased T cell responses 
induced by homologous Gag immunization also impli-
cate that these widely sought after responses can be 
induced by full length protein in most animals, while 
obtaining humoral responses against Env. Future stud-
ies should include analysis of Gag and CE responses to 
more distant Gag sequences, to provide an even broader 
knowledge of the perspective of homologous virus 
encoded VLP vaccines.
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